This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer (PFE) Gets FDA Nod for Bivalent COVID Jab in Infants
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech receive FDA label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as a single booster dose in young children under five years.
Deciphera Pharmaceuticals, Inc. (DCPH) Soars 10.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
BioNTech SE Sponsored ADR (BNTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
BioNTech SE Sponsored ADR (BNTX) closed the most recent trading day at $129.77, moving +1.82% from the previous trading session.
BioNTech (BNTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
BioNTech's (BNTX) fourth-quarter COVID-19 vaccine sales are likely to have declined with the pandemic largely in control. Updates on the company's booster dose authorization status and pipeline will be in focus.
BioNTech SE Sponsored ADR (BNTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
BioNTech SE Sponsored ADR (BNTX) closed at $131.54 in the latest trading session, marking a +0.59% move from the prior day.
BioNTech SE Sponsored ADR (BNTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $130.86, marking a -1.84% move from the previous day.
BioNTech SE Sponsored ADR (BNTX) Stock Moves -0.79%: What You Should Know
by Zacks Equity Research
BioNTech SE Sponsored ADR (BNTX) closed at $137.53 in the latest trading session, marking a -0.79% move from the prior day.
BioNTech SE Sponsored ADR (BNTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
BioNTech SE Sponsored ADR (BNTX) closed the most recent trading day at $143.92, moving +0.64% from the previous trading session.
BioNTech SE Sponsored ADR (BNTX) Stock Moves -0.68%: What You Should Know
by Zacks Equity Research
In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $141.15, marking a -0.68% move from the previous day.
Implied Volatility Surging for BioNTech (BNTX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to BioNTech (BNTX) stock based on the movements in the options market lately.
BioNTech SE Sponsored ADR (BNTX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
BioNTech SE Sponsored ADR (BNTX) closed the most recent trading day at $144.40, moving +0.94% from the previous trading session.
Pfizer (PFE) Q4 Earnings Top, 2023 View Disappoints, Stock Down
by Zacks Equity Research
Pfizer (PFE) beats estimates for Q4 earnings and sales. Its 2023 financial outlook falls short of expectations. Stock down in pre-market trading.
The Zacks Analyst Blog Highlights Pfizer/BioNTech, Moderna and Novavax
by Zacks Equity Research
Pfizer/BioNTech, Moderna and Novavax are included in this Analyst Blog.
Novavax (NVAX) COVID Jab Aids Growth, Overdependence a Challenge (revised)
by Zacks Equity Research
Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.
FDA Panel Endorses Simplification of COVID-19 Vaccine Strategy
by Zacks Equity Research
An FDA advisory committee unanimously votes in favor of using the same COVID-19 vaccine strain composition for primary series and booster doses.
Can Pfizer (PFE) Beat Expectations This Earnings Season?
by Zacks Equity Research
Higher alliance revenues from Eliquis, higher sales of Prevnar vaccines and drugs like Vyndaqel/Vyndamax are likely to have contributed to Pfizer's (PFE) sales growth in Q4.
Novavax (NVAX) COVID Jab Aids Growth, Overdependence A Woe
by Zacks Equity Research
Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.
Novavax (NVAX) Gets Nod for COVID-19 Booster Jab in South Korea
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine gets approval in South Korea as a booster dose in adults 18 years and older.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Novavax (NVAX) Names John Jacobs as New CEO, Shares Rise
by Zacks Equity Research
Novavax (NVAX) appoints John C. Jacobs as its new president and chief executive officer, effective Jan 23, 2023.
Novavax (NVAX) Starts A New Study on COVID-Flu Combo Jab
by Zacks Equity Research
Novavax (NVAX) initiates a mid-stage study evaluating its COVID-19-Influenza combination and standalone influenza vaccines in adults aged 50 through 80 years.
Are Investors Undervaluing BioNTech (BNTX) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 Big Drug, Biotech Stocks to Boost Your Portfolio in 2023
by Kinjel Shah
Here we discuss three big drug and biotech companies, Sanofi (SNY), GSK (GSK) and BioNTech (BNTX), which may prove to be good bets for your portfolio next year.
Moderna's (MRNA) BA.1 Omicron Booster Gets CHMP Nod for Kids
by Zacks Equity Research
The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.1 subvariant, for young children aged between six and 11 years.
FDA Delays Decision on AstraZeneca (AZN), Merck's Lynparza sNDA
by Zacks Equity Research
The FDA extends the review period of AstraZeneca (AZN)/Merck's filing seeking label expansion for Lynparza's indication in prostate cancer. The FDA intends to use this time to review the submission.